

Lawrence Berkeley National Laboratory

Recent Work

Title

EXCRETION RATES OF ASCITES TUMORE CELL COMPONENTS AS A FUNCTION OF DRUG TREATMENT

Permalink

<https://escholarship.org/uc/item/5ng7g41n>

Author

Hughes, Ann M.

Publication Date

1978-06-01

Submitted to NATURE

LBL-7927
Preprint

C.2

EXCRETION RATES OF ASCITES TUMOR CELL COMPONENTS
AS A FUNCTION OF DRUG TREATMENT

Ann M. Hughes and Melvin Calvin

RECEIVED
LAWRENCE
BERKELEY LABORATORY

June 1978


AUG 15 1978

LIBRARY AND
DOCUMENTS SECTION

Prepared for the U. S. Department of Energy
under Contract W-7405-ENG-48

TWO-WEEK LOAN COPY

This is a Library Circulating Copy
which may be borrowed for two weeks.
For a personal retention copy, call
Tech. Info. Division, Ext. 6782



LBL-7927

C.2

DISCLAIMER

This document was prepared as an account of work sponsored by the United States Government. While this document is believed to contain correct information, neither the United States Government nor any agency thereof, nor the Regents of the University of California, nor any of their employees, makes any warranty, express or implied, or assumes any legal responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by its trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof, or the Regents of the University of California. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof or the Regents of the University of California.

EXCRETION RATES OF ASCITES TUMOR CELL COMPONENTS
AS A FUNCTION OF DRUG TREATMENT

Ann M. Hughes and Melvin Calvin

Laboratory of Chemical Biodynamics
Lawrence Berkeley Laboratory
University of California
Berkeley, California 94720

We have previously reported the chemotherapeutic effect of rifamycin derivatives on an ascites tumor, using increased life span as a criterion.⁽¹⁾ These derivatives inhibit (1) RNA-instructed DNA polymerase in crude viral extracts; (2) virus-induced transformation in tissue cultures; and (3) the growth of tumors in vivo.⁽²⁾ One rifamycin derivative, rifazone-8₂ (R-8₂), not only inhibits transformation in chick fibroblasts but affects the growth of transformed cells.⁽³⁾ The present study demonstrates that rifampicin and R-8₂ act as cytotoxic (rather than cytostatic) agents against some ascites cell lines.

In order to distinguish between a cytotoxic and a cytostatic effect on ascites cells, we have adopted a technique developed by Hofer et al.⁽⁴⁾, in which cells are labeled with ¹²⁵I-iododeoxyuridine (¹²⁵IUDR). This is a convenient method for following the rate of cell death in individual live mice. Briefly, the technique consists of labeling tumor cells in vivo with ¹²⁵IUDR, which is incorporated exclusively into deoxyribonucleic acid.^(5,6,7) The labeled cells are then inoculated into non-radioactive mice. The rate of cell death can be monitored by following the loss of radioactivity from the live mice, since the ¹²⁵I remains with the tumor cells until they die, at which time less than 3-5% of the isotope is reutilized in proliferating mouse tissue.⁽⁸⁾

If a cytotoxic drug acts by killing an additional fraction of tumor cells beyond the small percentage normally dying, this effect will be reflected in an increased excretion of ¹²⁵I. On the other hand, if the drug only prolongs the generation time of the tumor cells, this effect should be evident in an increased survival time of the host animal without an increase in the rate of ¹²⁵I excretion. Thus one can distinguish between a cytotoxic and cytostatic effect.⁽⁹⁾

The ascites cell lines studied included TA3 and Ehrlich's (both maintained in LAF/J female mice), and L1210, MTX, and L5178Y (maintained in C₃D₂F₁/J female mice). The TA3 is an adenocarcinoma, the Ehrlich's is derived from a mammary carcinoma, and the L1210, MTX and L5178Y are all leukemic lines. All cell lines were carried by weekly i.p. transfer of 10⁵ cells into the appropriate hosts. For experimental purposes, 10⁶ cells were inoculated into the appropriate strain of donor mice. Four days later these mice received 2-4 μCi ¹²⁵IUDR i.p., divided into two doses, 6 hours apart. Twenty-four hours after the first dose, the labeled cells were harvested, washed twice with Earle's Balanced Salt Solution, and inoculated into recipient mice. All concentrations were adjusted so that the total inoculum was contained in 0.2 ml. All cell preparation was done at 4°C. For experiments involving TA3 cells, the inoculum was 10⁶ cells/animal; for Ehrlich's, 4x10⁶; and for the three leukemic lines, 10⁷. To avoid accumulation of ¹²⁵I in the thyroid, the drinking water of these mice was supplemented with 0.1% NaI, beginning 1-2 days before the experiment. In order to determine how fast the breakdown products of dead cells were being excreted, some animals were inoculated with cells which had been killed by heating in a waterbath at 65°C for 15 minutes. The radioactivity in individual mice was monitored immediately after inoculation and daily thereafter. The measuring equipment consisted of a pair of coaxially mounted, 3 mm thick NaI crystals, (12.5 cm diameter), equipped with a multichannel analyzer. The pulses from the 0.035 mev Te x-rays were counted. Individual mice were placed at the midpoint of the central axis of the crystals (set 5.5 cm apart), with the midline of the mouse at right angles to the crystals.

The rifamycin derivatives investigated were rifampicin (Rif) and R-8₂.⁽¹⁰⁾ The drugs were suspended in 0.5% methylcellulose solution in 0.9% NaCl (MeC) at a concentration of 10 mg/ml. Control mice were injected with MeC. In

all experiments the first drug injection (4 mg) was made 12 hours after tumor inoculation. Subsequent injections of 2 mg were made 24 and 72 hours after cell inoculation. To determine whether the drugs affected the excretion of dead cells, in the experiments with Ehrlich's cells, drugs were injected into mice which had received killed cells (Fig. 1A). All injections were i.p.

Based on the excretion rate of ^{125}I , Rif and R-8₂ are effective against Ehrlich's and TA3 ascites cells in LAF/J female mice, and the effect is cytotoxic rather than cytostatic (Fig. 1 A&B). These drugs did not influence the rate of excretion of activity from killed cells (Fig. 1 A). Therefore, the differences in loss of activity in control mice (MeC) and drug-treated (Rif & R-8₂) is not due to an effect of the drugs on the ^{125}I excretion system itself. Rif is slightly more effective than R-8₂, probably because of its greater water solubility.⁽¹⁾ However, the drugs show little effect against the leukemic lines (Fig. 2 A,B&C). The latter observation is in agreement with the lack of therapeutic activity of these drugs against radiation-induced thymic lymphomas (unpublished data), and is supported by our observation of an increase of leukemia in rats injected with dimethylbenzanthracene and treated with rifamycin derivatives.⁽¹¹⁾

In conclusion, Rif and R-8₂ are shown to be effective anti-tumor drugs against some cell lines, by selectively killing the tumor cells. The reason behind the resistance of leukemic cells to rifamycin derivatives is not understood at present and warrants further study. The existence of both susceptible and resistant cells provides an opportunity for further probing the mechanism of action of these drugs.

We are indebted to Dr. Patricia Durban for the use of the radioactivity counting equipment.

This research was supported by the Division of Biomedical and Environmental Research of the U.S. Department of Energy.


REFERENCES

1. Hughes, A.M., Tenforde, T.S., Calvin, M., Bissell, M.J., Tischler, A.N. and Bennett, E.L., Oncology, 35:76-82 (1978).
2. Joss, U.R., Hughes, A.M. and Calvin, M., Nature New Biol., 242:88-90 (1973).
3. Bissell, M.J., Hatie, C., Tischler, A.N. and Calvin, M., Proc. Natl. Acad. Sci. U.S.A., 71:2520-2524 (1974).
4. Hofer, K.G., Rosenoff, S., Prenskey, W. and Hughes, W.L., Nature, 221:576-577 (1969).
5. Hofer, K.G. and Hughes, W.L., Cancer Research, 30:236-243 (1970).
6. Commerford, S.L., Nature, 206:949-950 (1965).
7. Hughes, W.L., Commerford, S.L., Gitlin, D., Krueger, R.C., Schultze, B., Shah, V. and Reilly, P., Fed. Proc., 23:640-648 (1964).
8. Hofer, K.G., Prenskey, W. and Hughes, W.L., J. Nat. Cancer Inst., 43:763-773 (1969).
9. Hofer, K.G., Cancer Chemotherapy Reports, 53:273-281 (1969).
10. Tischler, A.N., Thompson, F.M., Libertini, L.J. and Calvin, M., J. Med. Chem., 17:948-952 (1974).
11. Hughes, A.M. and Calvin, M., Cancer Letters, 2:5-10 (1976).

LEGENDS FOR FIGURES


Fig. 1. Rate of loss of ^{125}I from mice inoculated with ^{125}I UDR-labeled ascites cells and treated with drugs. A = Ehrlich's, B = TA3. Data points marked with open symbols are for animals inoculated with live cells; with closed, animals inoculated with killed cells. Each point represents the average of 10 mice. Abbreviations: R-8₂ = rifazone-8₂, Rif = rifampicin, MeC = methylcellulose, DCC = killed cell control.

Fig. 2. Rate of loss of ^{125}I from mice inoculated with ^{125}I UDR-labeled ascites cells and treated with drugs. A = L1210, B = MTX, C = L5178Y. Data points marked with open symbols are for animals inoculated with live cells; with closed, animals inoculated with killed cells. Each point represents the average age of 10 mice. Abbreviations: R-8₂ = rifazone-8₂, Rif = rifampicin, MeC = methylcellulose, DCC = killed cell control.




XBL 785-2531

Fig 1. - Hughes + Calvin




XBL 785-2532

Fig. 1 - Hughes + Calvin




XBL 785-2533

Fig. 2 - Hughes + Calvin



XBL 785-2534

Fig. 2 - Hughes + Calvert



XBL 785-2535

Fig. 2 - Hughes & Calvert

This report was done with support from the Department of Energy. Any conclusions or opinions expressed in this report represent solely those of the author(s) and not necessarily those of The Regents of the University of California, the Lawrence Berkeley Laboratory or the Department of Energy.

TECHNICAL INFORMATION DEPARTMENT
LAWRENCE BERKELEY LABORATORY
UNIVERSITY OF CALIFORNIA
BERKELEY, CALIFORNIA 94720

6